Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5981436 | 0.98 | GPR35 (0.41) | GPR35BCL2L1DAOALDH1A1KDM4E | |
| SCHEMBL2016377 | 0.84 | KDR (0.46) | RPS6KB1PLK4AURKADAPK3CHEK2 | |
| SCHEMBL4461503 | 0.73 | GPR35 (0.39) | GPR35BCL2L1ALDH1A1KDM4EMEN1 | |
| SCHEMBL6205077 | 0.70 | GPR35 (0.42) | GPR35BCL2L1DAOALDH1A1KDM4E | |
| SCHEMBL31081263 | 0.69 | CCNE1 (0.43) | GPR35ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL24163133 | 0.68 | — | — | |
| SCHEMBL21167345 | 0.68 | — | — | |
| SCHEMBL31619547 | 0.66 | GPR35 (0.54) | GPR35BCL2L1DAOALDH1A1KDM4E | |
| SCHEMBL3835960 | 0.66 | MAP3K8 (0.39) | GPR35DAOALDH1A1KDM4EMEN1 | |
| SCHEMBL4136428 | 0.65 | TRPA1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365819-A2 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | Mangosuthu University Of Technology (ZA) | 2018-08-29 | — | — | EP | claimed |
| WO-2017070719-A2 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2017-04-27 | — | — | WO | claimed |
| CN-102702222-A | Synthetic method of 3-methyl-1-substituted 1-H-thieno[2, 3-c] pyrazol-5-carboxylate (5-sulfonyl dimethylamine-2 methyl phenyl)-amide | SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-03 | — | — | CN | claimed |
| EP-1904503-A1 | 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-04-02 | — | — | EP | claimed |
| WO-2007009898-A1 | 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-25 | — | — | WO | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| CN-102702222-A | Synthetic method of 3-methyl-1-substituted 1-H-thieno[2, 3-c] pyrazol-5-carboxylate (5-sulfonyl dimethylamine-2 methyl phenyl)-amide | SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-03 | — | — | CN | disclosed |
| WO-2007009898-A1 | 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-25 | — | — | WO | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1711177-A1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | Pfizer Italia S.r.l. (IT) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006056697-A1 | SUBSTITUTED THIENO[2,3-C]PYRAZOLES, METHOD FOR THE PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1569954-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005074922-A1 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | PFIZER ITALIA S.R.L. (IT) | 2005-08-18 | — | — | WO | disclosed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | GPR35 1122/4885BCL2L1 4326/4885DAO 2673/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | GPR35 1122/4885BCL2L1 4326/4885DAO 2673/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | GPR35 1122/4885BCL2L1 4326/4885DAO 2673/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | GPR35 2110/4885BCL2L1 2582/4885DAO 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.